Related Experiment Videos
Beta 2 glycoprotein I--function in health and disease
Spiros Miyakis1, Bill Giannakopoulos, Steven A Krilis
1Department of Immunology, Allergy and Infectious Diseases, University of New South Wales, St. George Hospital, 2 South Street, Kogarah, NSW 2217, Australia.
Thrombosis Research
|October 28, 2004
Summary
Beta-2 glycoprotein I (beta2GPI) regulates blood clotting by inhibiting Factor XI activation. Autoantibodies against beta2GPI in antiphospholipid syndrome may disrupt this, potentially causing thrombosis.
Area of Science:
- Coagulation cascade
- Immunology
- Protein-protein interactions
Background:
- Beta-2 glycoprotein I (beta2GPI) is a key autoantigen in antiphospholipid syndrome (APS).
- Beta2GPI interacts with phospholipids and coagulation factors, influencing hemostasis.
- Its precise physiological role in coagulation remains under investigation.
Purpose of the Study:
- To investigate the interaction between beta2GPI and Factor XI (FXI).
- To determine how this interaction affects FXI activation.
- To explore the implications for thrombosis in APS.
Main Methods:
- In vitro binding assays to assess beta2GPI and FXI interaction.
- Measurement of FXI activation in the presence of beta2GPI and its cleaved forms.
- Analysis of FXI activation by thrombin and FXIIa.
Main Results:
- Beta2GPI binds FXI in vitro, inhibiting its activation by thrombin and FXIIa.
- Proteolytic cleavage of beta2GPI's fifth domain abolishes FXI activation inhibition.
- Cleaved beta2GPI shows reduced phospholipid binding but retains FXI binding capacity.
Conclusions:
- Beta2GPI attenuates the contact activation pathway by inhibiting FXI activation.
- Dysregulation of this beta2GPI-FXI interaction by autoantibodies may contribute to APS-related thrombosis.